PathMaker Neurosystems said today that it won a grant from BpiFrance to support the company’s MyoRegulator neuromodulation device designed to treat patients with neuromotor spasticity.
The MyoRegulator device, based on PathMaker’s DoubleStim technology, is designed to provide simultaneous, non-invasive stimulation at spinal and peripheral locations, the Boston and Paris-based company said.
The grant will support the initiation of a clinical development program in France, through which the company will collaborate with researchers and clinicians at Paris’ Brain and Spine Institute which will operate as the European clinical trial site for the MyoRegulator.
“We are truly pleased to have received this support from Bpifrance. After comprehensive review of our company and technology, Bpifrance is demonstrating confidence in our efforts and we are thankful for the support and validation from this leading institution,” prez & CEO Dr. Nader Yaghoubi said in a press release.
Last month, PathMaker Neurosystems announced that it will work with France’s Brain and Spine Institute to launch a human clinical trail of its MyoRegulator neromodulation system.
The company said it plans to initiate clinical trials in France later this year, and that data from the trials would be used to support CE Mark clearance in the European Union for the system.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!